Your session is about to expire
← Back to Search
Pegunigalsidase Alfa for Fabry Disease (Bright51 Trial)
Bright51 Trial Summary
This trial is testing how safe and effective a drug is in treating Fabry disease in adults who have completed another trial successfully.
Bright51 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBright51 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Bright51 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use effective birth control during and for 2 weeks after the treatment.
- Group 1: Experimental open label
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How does pegunigalsidase alfa compare to other treatments in terms of safety?
"There is some clinical evidence to support the efficacy of pegunigalsidase alfa, as well as multiple rounds of data indicating its safety. For these reasons, our team has given it a score of 3."
At how many facilities is this research being conducted?
"Emory University School of Medicine in Atlanta, Georgia, O & O Alpan in Fairfax, Virginia, Infusion Associates in Grand Rapids, Michigan are a few of the locations where this clinical trial is enrolling patients. There are also 8 other locations."
Are new patients being recruited for this clinical trial?
"This particular clinical trial is not presently recruiting patients. The study was initially posted on November 6th, 2018, and was most recently updated on February 14th, 2022. There are 23 other clinical trials actively recruiting patients with fabry disease and 2 studies for pegunigalsidase alfa that are also recruiting patients."
How many people are willing to try this new medication?
"Unfortunately, this particular trial is not currently enrolling patients. Although, there are 23 other trials for fabry disease and 2 studies for pegunigalsidase alfa that are currently looking for participants. This particular trial was originally posted on 11/6/2018 and was most recently edited on 2/14/2022."
Are there previous instances of research involving pegunigalsidase alfa?
"Currently, there are two ongoing clinical trials researching pegunigalsidase alfa. These are both in Phase 3. Most of the investigations for pegunigalsidase alfa are based in Iowa City, Iowa; however, there are a total of 48 clinical trial locations for pegunigalsidase alfa."
Does this research paper break new ground?
"Research surrounding pegunigalsidase alfa began in 2018. The first 110 participants were involved in a Phase 1 clinical trial sponsored by Protalix. After the success of the initial Phase 1 trial, the drug was approved for Phase 3 testing. Now, there are 2 live trials involving pegunigalsidase alfa with recruitment happening in 21 cities and 15 countries."
Share this study with friends
Copy Link
Messenger